Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nicardipine Hydrochloride

FDA-approved product (capsule, oral), marketed as Cardene, Cardene In 0.83% Sodium Chloride In Plastic Container, Cardene In 0.86% Sodium Chloride In Plastic Container and 7 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nicardipine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dihydropyridine derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae7.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nicardipine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nicardipine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • NICardipine Neuroprotection in AortiC Surgery (NICNACS)

    NCT00508118 · start 2008-01

    Registered record
    Registry ID
    NCT00508118
    Conditions
    Aortic Aneurysm, Thoracic
    Interventions
    Nicardipine; 0.9% saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-01
    Completion
    2008-04
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAortic Aneurysm, Thoracic
    InterventionNicardipine; 0.9% saline
    PhasePhase 2
    Registry statusTerminated

  • Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage

    NCT00226096 · start 2005-11

    Registered record
    Registry ID
    NCT00226096
    Conditions
    CVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial Hemorrhages
    Interventions
    Labetalol Hydrochloride; Metoprolol tartrate; Hydralazine Hydrochloride; Glycerol Trinitrate; Phentolamine mesylate; Nicardipine; Urapidil; Esmolol; Clonidine; Enalaprilat; Nitroprusside
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-11
    Completion
    2007-09
    Enrolment
    404

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial Hemorrhages
    InterventionLabetalol Hydrochloride; Metoprolol tartrate; Hydralazine Hydrochloride; Glycerol Trinitrate +7 more
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

    NCT00490464 · start 2004-06

    Registered record
    Registry ID
    NCT00490464
    Conditions
    Subarachnoid Hemorrhage; Intracerebral Hemorrhage
    Interventions
    Nicardipine and Nipride
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2004-06
    Completion
    2007-02
    Enrolment
    163

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubarachnoid Hemorrhage; Intracerebral Hemorrhage
    InterventionNicardipine and Nipride
    PhaseNot recorded
    Registry statusCompleted

  • Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)

    NCT00093925 · start 2004-05

    Registered record
    Registry ID
    NCT00093925
    Conditions
    Hypertension
    Interventions
    clevidipine; nicardipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-05
    Completion
    2006-09
    Enrolment
    739

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclevidipine; nicardipine
    PhasePhase 3
    Registry statusCompleted

  • Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension

    NCT00684489 · start 2003-09

    Registered record
    Registry ID
    NCT00684489
    Conditions
    Hypertension
    Interventions
    clinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionclinical hypertension specialist-no specific med. Any anti-hypertension meds.; renin guided therapeutics-no specific med. Any anti-hypertensive med.
    PhaseNot applicable
    Registry statusCompleted